Jessica Carter, NP
Psychiatric/Mental Health · Greensboro, NCNPI 1114937224
Payments from drug & device makers
Across 162 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$345
- Alkermes, Inc.$330
- AbbVie$229
- Johnson & Johnson$178
- Lundbeck LLC$157
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$154
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,55698%
- Education$472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 40 | $345 |
| Alkermes, Inc. | 18 | $330 |
| AbbVie | 20 | $229 |
| Johnson & Johnson | 7 | $178 |
| Lundbeck LLC | 8 | $157 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $154 |
| Otsuka America Pharmaceutical, Inc. | 6 | $131 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $122 |
| Teva Pharmaceuticals USA, Inc. | 7 | $114 |
| Supernus Pharmaceuticals, Inc. | 5 | $84 |
| Corium, LLC | 5 | $84 |
| Masimo Corporation | 1 | $81 |
| Acadia Pharmaceuticals Inc | 3 | $72 |
| Merck | 4 | $61 |
| Vanda Pharmaceuticals Inc. | 3 | $58 |
| Neurocrine Biosciences, Inc. | 3 | $56 |
| Eisai Inc. | 3 | $52 |
| Adlon Therapeutics L.p. | 2 | $39 |
| Jazz Pharmaceuticals Inc. | 2 | $39 |
| Neos Therapeutics, LP | 2 | $31 |
| Avanir Pharmaceuticals, Inc. | 2 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Tris Pharma Inc | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Almatica Pharma LLC | 1 | $20 |
| Aytu Biopharma, Inc. | 1 | $20 |
| Ironshore Pharmaceuticals Inc. | 1 | $19 |
| OWP Pharmaceuticals, Inc. | 1 | $18 |
| Noven Therapeutics, LLC | 1 | $15 |
How this compares
$2,603 in reported general payments places this provider in the 80th percentile of 947 psychiatric/mental health providers in North Carolina.
See all psychiatric/mental health providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 27 | $214,060 |
| Austedo XrDeutetrabenazine | 11 | $194,715 |
| IngrezzaValbenazine Tosylate | 11 | $80,257 |
| RexultiBrexpiprazole | 19 | $48,756 |
| AuvelityDextromethorphan Hbr/Bupropion | 32 | $36,304 |
| VraylarCariprazine Hcl | 16 | $24,851 |
| VyvanseLisdexamfetamine Dimesylate | 31 | $14,535 |
| DayvigoLemborexant | 18 | $7,252 |
| Duloxetine Hcl | 175 | $3,336 |
| Lurasidone Hcl | 46 | $3,193 |
| Bupropion XlBupropion Hcl | 129 | $2,846 |
| Aripiprazole | 66 | $2,517 |
| Buspirone Hcl | 90 | $2,133 |
| Oxcarbazepine | 18 | $1,772 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 74 | $1,671 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $114 | $408,77638 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $56 | $80,25711 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $131 | $48,75619 claims |
| Axsome Therapeutics, Inc.Auvelity | $21 | $36,30432 claims |
| AbbVieVraylar | $229 | $24,85116 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $122 | $14,53531 claims |
| Eisai Inc.Dayvigo | $52 | $7,25218 claims |
| Almatica Pharma LLCSertraline Hcl | $20 | $1,445100 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 947 psychiatric/mental health providers in North Carolina.
Other psychiatric/mental health in Greensboro
- April NandigamGreensboro$88K
- Brittany MitchellGreensboro$12K
- Lisa PoulosGreensboro$10K
- Marian FriedmanGreensboro$9K
- Brian WhiteGreensboro$8K
- Desiree MatthewsCharlotte$807K
- Benedetto PalomboCharlotte$671K
- Clarence RunnelsCreedmoor$339K
- Lisa SuddrethGastonia$111K
- Hannah NealeyFuquay Varina$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.